peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Biopharma to host conference call to provide interim results for January-March 2022 and Business Update

8 Apr 2022, 08:00

Lund, Sweden April 8, 2022 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2022 at 8:00 CET on April 21, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call. Link to presentation

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 20 3936 2999

United States: +1 646 664 1960

The webcast will be available on https://streams.eventcdn.net/hansa/q1-2022/

Updated Calendar and Events 2022

April 13, 2022               Needham Healthcare Conference 2022

April 21, 2022              Interim Report for January-March 2022

April 21, 2022               Kempen Life Sciences Conference 2022, Amsterdam

April 27, 2022               Redeye Orphan Drugs 2022, Stockholm

May 15, 2022               ABG Life Science Summit, Stockholm

May 16, 2022               European Midcap Event, Copenhagen

June 16, 2022              Annual General Meeting 2022

July 12, 2022                William Blair’s Biotech Focus Conference 2022, New York

July 21, 2022               Half year 2022 report

Aug 9, 2022                  BTIG Biotechnology Conference 2022, New York

Aug 10, 2022                Canaccord Annual Growth Conference, Boston

Sept 7-8, 2022              Pareto annual healthcare conference, Stockholm

Sept 7-8, 2022              Citi's 17th Annual BioPharma Conference, Boston

Oct 20, 2022                 Interim Report for January-September 2022

Nov 23, 2022                Økonomisk Ugebrev Life Science konference, Copenhagen

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com.